IPOdesktop • Wed, Jun. 18
- A development stage emerging therapeutic and diagnostic company focusing on microRNA and its role in oncology.
- Entered into agreements with an affiliate of the Ohio State University (OSU), to exclusively license a portfolio of approximately 100 pending patent applications.
- Has not yet initiated any clinical trials or validated its candidate diagnostic tests.
There are no Transcripts on MCLB.
We currently have no Breaking News on this stock.
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
MCLB vs. ETF Alternatives
Currently, there's no company description for MCLB.
Country: United States
Other News & PR